Featured Articles
-
West Announces Landmark Collaboration With Corning In Pharmaceutical Injectable Drug Delivery
1/26/2022
The exclusive long-term supply and development agreement includes a multimillion-dollar capital and R&D investment in Corning to enable advanced drug containment and delivery system solutions.
-
West Pharmaceuticals And MEDX Xelerator Sign Strategic Collaboration
11/23/2021
The agreement is focused on identifying and developing early-stage medical technology innovation. Under the terms of the accord, West will provide funding for joint venture creations at the incubator and will have the option to further invest in these same projects, alongside the incubator, if the projects mature into portfolio companies.
-
West Launches New Vial2Bag Advanced™ 20mm Admixture Device
10/22/2020
West Pharmaceutical Services, Inc. (NYSE: WST), West Pharmaceutical Services, Inc. (West) is pleased to announce FDA 510(k) clearance and launch of its Vial2Bag Advanced™ 20mm Admixture Device.
-
West Expands NovaGuard™ Platform of Products for Safe and Effective Injectable Drug Delivery
7/2/2013
West Pharmaceutical Services, Inc., a leading global developer and manufacturer of components and systems for injectable drug delivery, today announced the expansion of the NovaGuard portfolio of needle safety products.
-
West And Janssen Biotech Agreement To Develop A New Self-injection Technology
9/5/2012
West Pharmaceutical Services announced an agreement with Janssen Biotech, Inc. to collaborate on the development and manufacturing of an innovative self-injection product.
-
Holistic QbD: A Key To Improved Profitability And Sustained Competitive Advantage With Sterile Pharmaceutical Products
8/9/2012
Pharmaceutical companies are faced with assuring that new quality and compliance paradigms can be met while facilitating profitability to continue adequate business reinvestment. By Fran DeGrazio, Vice President, Global Research and Development, Pharmaceutical Packaging Systems West Pharmaceutical Services, Inc.
-
Sterilization Of Ready-To-Use Components
12/2/2011
Inadequate aseptic processing operations, human error, high endotoxin levels, microbial contamination and insufficient sterility testing have all generated FDA warning letters.
-
The Importance Of A Human Centered Approach To Product Development
To meet the needs of patients, life-saving device innovations are needed for the next generation of delivery devices. As drug manufacturers explore the device world, human factors are a key consideration.
-
Gene Therapy: Maintaining Sterility At Low Temperature Storage
A gene therapy for pediatric Spinal Muscular Atrophy required a leak and break-resistant container which maintains sterility over product shelf life, through freeze and defrost cycles.
-
De-Risking Visible Particles Through Component Selection
Explore a summary of the FDA’s recent draft guidance “Inspection of Injectable Products for Visible Particulates” and how it applies to components.